Last reviewed · How we verify
A Study of LCAR-AIO in Subjects With Relapsed/Refractory Autoimmune Diseases
This is a prospective, single-arm, open-label, dose-exploration and expansion clinical study of LCAR-AIO in adult subjects with relapsed/refractory autoimmune diseases.
Details
| Lead sponsor | Nanjing Legend Biotech Co. |
|---|---|
| Phase | EARLY_PHASE1 |
| Status | WITHDRAWN |
| Start date | Tue Jun 17 2025 00:00:00 GMT+0000 (Coordinated Universal Time) |
| Completion | Tue Jun 17 2025 00:00:00 GMT+0000 (Coordinated Universal Time) |
Conditions
- Relapsed/Refractory Autoimmune Diseases
Interventions
- LCAR-AIO T cells
Countries
China